Trillium Therapeutics Inc. - Press Releases

Press Releases

2020 2019 2018 2017 2016 2015 2014 2013

Trillium Announces Voting Results From the Annual and Special Meeting of Shareholders

July 6, 2020

Trillium Therapeutics Provides Update on the Phase I Dose Escalation Study of Its CD47 Blocker TTI-622 at the ASCO20 Virtual Scientific Program

May 29, 2020

Trillium Therapeutics Reports First Quarter 2020 Financial and Operating Results

May 15, 2020

Trillium Therapeutics to Present Data on CD47 Blocker TTI-622 in Advanced Relapsed or Refractory Lymphoma at the ASCO20 Virtual Scientific Program

May 13, 2020

Trillium Therapeutics Announces “At-The-Market” Equity Program

May 6, 2020

Trillium Therapeutics Provides Business Update in Response to the Covid-19 Pandemic

April 8, 2020

Trillium Therapeutics Reports Annual Financial and Operating Results

March 10, 2020

Trillium Therapeutics Responds to Market Activity

February 28, 2020

Trillium Therapeutics Announces Changes to Its Board of Directors

February 7, 2020

Trillium Closes US$117 Million Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares

January 29, 2020

Trillium Announces Pricing of US$101,700,000 Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares

January 23, 2020

Trillium Announces Proposed Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares

January 22, 2020

Trillium Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

January 16, 2020

Trillium Therapeutics Provides Update on Its TTI-621 and TTI-622 CD47 Programs

January 7, 2020